Literature DB >> 15293599

Tuberculosis in HIV-infected persons in the context of wide availability of highly active antiretroviral therapy.

E Girardi1, G Antonucci, P Vanacore, F Palmieri, A Matteelli, E Iemoli, S Carradori, B Salassa, M Bruna Pasticci, M C Raviglione, G Ippolito.   

Abstract

Highly active antiretroviral therapy (HAART) greatly reduces the risk of developing tuberculosis for HIV-infected persons. Nonetheless, HIV-associated tuberculosis continues to occur in countries where HAART is widely used. To identify the characteristics of HIV-infected persons who develop tuberculosis in the context of the availability of HAART, the current authors analysed data taken from 271 patients diagnosed, in Italy, during 1999-2000. These patients represent 0.7% of the 40,413 HIV-infected patients cared for in the clinical units participating in this current study. From the data it was observed that 20 patients (7.4%) had a previous episode of tuberculosis whose treatment was not completed. Eighty-one patients (29.9%) were diagnosed with HIV at tuberculosis diagnosis, 108 (39.8%) were aware of their HIV status but were not on antiretroviral treatment and 82 (30.3%) were on antiretroviral treatment. Patients on antiretroviral treatment were significantly less immunosuppressed than patients with HIV diagnosed concurrently with tuberculosis, or other patients not on antiretrovirals (median CD4 lymphocytes count: 220 cells x mm(-3) versus 100 cells x mm(-3), and 109 cells x mm(-3), respectively). No significant differences in clinical presentation of tuberculosis according to antiretroviral therapy status were recorded. Failure of tuberculosis control interventions (e.g. noncompletion of treatment) and of HIV care (delayed diagnosis of HIV infection and suboptimal uptake of therapy) may contribute to continuing occurrence of HIV-associated tuberculosis in a country where highly active antiretroviral therapy is largely available. However, a significant proportion of cases occur in patients who are on antiretroviral treatment.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15293599     DOI: 10.1183/09031936.04.00109303

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  15 in total

1.  Antiretroviral therapy for tuberculosis control in nine African countries.

Authors:  Brian G Williams; Reuben Granich; Kevin M De Cock; Philippe Glaziou; Abhishek Sharma; Christopher Dye
Journal:  Proc Natl Acad Sci U S A       Date:  2010-10-25       Impact factor: 11.205

2.  Tuberculosis risk before and after highly active antiretroviral therapy initiation: does HAART increase the short-term TB risk in a low incidence TB setting?

Authors:  April C Pettit; Cathy A Jenkins; Samuel E Stinnette; Peter F Rebeiro; Robert B Blackwell; Stephen P Raffanti; Bryan E Shepherd; Timothy R Sterling
Journal:  J Acquir Immune Defic Syndr       Date:  2011-08-01       Impact factor: 3.731

3.  Tuberculosis 2004: challenges and opportunities.

Authors:  Jeffrey Glassroth
Journal:  Trans Am Clin Climatol Assoc       Date:  2005

4.  Tuberculosis risk factors and mortality for HIV-infected persons receiving antiretroviral therapy in South Africa.

Authors:  Stephanus Komati; Pamela A Shaw; Nomso Stubbs; Monkwe J Mathibedi; Lizette Malan; Phumelele Sangweni; Julia A Metcalf; Henry Masur; Shaheen Hassim
Journal:  AIDS       Date:  2010-07-31       Impact factor: 4.177

Review 5.  HIV and tuberculosis: a deadly human syndemic.

Authors:  Candice K Kwan; Joel D Ernst
Journal:  Clin Microbiol Rev       Date:  2011-04       Impact factor: 26.132

6.  High rates of tuberculosis in patients accessing HAART in rural South Africa.

Authors:  Kogieleum Naidoo; Quarraisha Abdool Karim; Ambika Bhushan; Kasavan Naidoo; Nonhlanhla Yende-Zuma; Patricia K McHunu; Janet Frohlich; Farina Karim; Michele Upfold; Paul Kocheleff; Salim S Abdool Karim
Journal:  J Acquir Immune Defic Syndr       Date:  2014-04-01       Impact factor: 3.731

7.  Response to region of difference 1 (RD1) epitopes in human immunodeficiency virus (HIV)-infected individuals enrolled with suspected active tuberculosis: a pilot study.

Authors:  D Vincenti; S Carrara; O Butera; F Bizzoni; R Casetti; E Girardi; D Goletti
Journal:  Clin Exp Immunol       Date:  2007-08-03       Impact factor: 4.330

8.  Recurrent tuberculosis in HIV-infected patients in Rio de Janeiro, Brazil.

Authors:  Jonathan E Golub; Betina Durovni; Bonnie S King; Solange C Cavalacante; Antonio G Pacheco; Lawrence H Moulton; Richard D Moore; Richard E Chaisson; Valeria Saraceni
Journal:  AIDS       Date:  2008-11-30       Impact factor: 4.177

9.  Predictors of mortality in HIV-associated hospitalizations in Portugal: a hierarchical survival model.

Authors:  Sara S Dias; Valeska Andreozzi; Maria O Martins; Jorge Torgal
Journal:  BMC Health Serv Res       Date:  2009-07-23       Impact factor: 2.655

Review 10.  Immune reconstitution and "unmasking" of tuberculosis during antiretroviral therapy.

Authors:  Stephen D Lawn; Robert J Wilkinson; Marc C I Lipman; Robin Wood
Journal:  Am J Respir Crit Care Med       Date:  2008-01-17       Impact factor: 21.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.